REG - EKF Diagnostics Hldg - Share Buyback

EKF Diagnostics HoldingsAnnouncement

Yesterday 18:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260331:nRSe9342Ya&default-theme=true

RNS Number : 9342Y  EKF Diagnostics Holdings PLC  31 March 2026

 

 

EKF Diagnostics Holdings plc

("EKF" or the "Company")

 

Share Buyback

 

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics
business, announces that it has purchased a total of 100,000 of its ordinary
shares of 1p each in the capital of the Company ("Ordinary Shares") at a
weighted average price of 23.6 pence per share. The Ordinary Shares purchased
will be held in treasury. Harwood Capital Management has not sold any ordinary
shares to the Company as part of yesterday's purchases.

 

Aggregated information

 

 Date of purchase                       30 March 2026
 Number of Ordinary Shares purchased    100,000
 Highest price paid per Ordinary Share  23.6p
 Lowest price paid per Ordinary Share   23.6p
 Volume weighted average price paid     23.6p

 

 Transaction details

 

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (the Market
Abuse Regulation) (which forms part of domestic UK law pursuant to the
European Union (Withdrawal) Act 2018), a detailed breakdown of individual
trades is available below:

 

 Number of Ordinary Shares purchased  Transaction price (GBp)  Time of transaction  Trading venue
 50,000                               23.6p                    09:40:36             AIMX
 50,000                               23.6p                    10:23:51             AIMX

 

Total voting rights

 

Following the purchase, the Company's total issued share capital will consist
of 431,963,112 Ordinary Shares, of which 965,000 Ordinary Shares are held in
treasury. Therefore, the total number of Ordinary Shares carrying voting
rights will be 430,998,112. This figure may be used by shareholders as the
denominator for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest in, the
Company under the FCA's Disclosure Guidance and Transparency Rules.

 

 

 

This announcement contains inside information for the purposes of Article 7 of
EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the
European Union (Withdrawal) Act 2018).

 

 

The person responsible for arranging the release of this Announcement

on behalf of the Company is Julian Baines, Executive Chair.

 

 

 EKF Diagnostics Holdings plc                                www.ekfdiagnostics.com (http://www.ekfdiagnostics.com)
 Julian Baines, Executive Chair                               via Walbrook PR
 Gavin Jones, Chief Executive Officer
                                                                                           Tel: +44 (0)20 7496 3000

 Singer Capital Markets (Nominated Adviser & Broker)
 Phil Davies / Patrick Weaver

 Walbrook PR Limited              Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com (mailto:ekf@walbrookpr.com)
 Paul McManus / Alice Woodings    Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

 

 

 

About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com
(http://www.ekfdiagnostics.com) )

 

EKF is an AIM-listed global diagnostics business focussed on:

 

 ●    Point-of-Care analysers in the key areas of Hematology and Diabetes
 ●    Life Sciences services provide specialist manufacture of enzymes and custom
      products for use in diagnostic, food and industrial applications.

 

EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing
sites across the US and Germany, selling into over 120 countries world-wide.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCSDMFMFEMSEID



            Copyright 2019 Regulatory News Service, all rights reserved